Shares of Aprea Therapeutics (NASDAQ:APRE) have received a consensus broker rating score of 2.50 (Hold) from the two analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and one has given a buy recommendation to the company.
Analysts have set a 1-year consensus price objective of $28.50 for the company and are expecting that the company will post ($0.40) earnings per share for the current quarter, according to Zacks. Zacks has also given Aprea Therapeutics an industry rank of 58 out of 255 based on the ratings given to its competitors.
A number of brokerages have commented on APRE. JPMorgan Chase & Co. assumed coverage on shares of Aprea Therapeutics in a report on Monday, October 28th. They set a “neutral” rating and a $23.00 price objective on the stock. Royal Bank of Canada assumed coverage on shares of Aprea Therapeutics in a research report on Monday, October 28th. They set an “outperform” rating and a $33.00 target price on the stock. Morgan Stanley assumed coverage on shares of Aprea Therapeutics in a research report on Monday, October 28th. They set an “equal weight” rating and a $23.00 target price on the stock. Finally, ValuEngine downgraded shares of Aprea Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 14th.
In other Aprea Therapeutics news, CFO Scott M. Coiante bought 2,500 shares of the business’s stock in a transaction on Monday, October 7th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $37,500.00. Also, Director Johan Christenson bought 266,667 shares of the business’s stock in a transaction on Monday, October 7th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $4,000,005.00. Over the last 90 days, insiders have acquired 613,500 shares of company stock worth $9,202,500.
NASDAQ:APRE traded up $1.89 during mid-day trading on Friday, reaching $26.05. 209,729 shares of the company were exchanged, compared to its average volume of 87,556. Aprea Therapeutics has a 12 month low of $15.10 and a 12 month high of $32.04. The firm’s fifty day moving average is $25.08.
Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Thursday, November 14th. The company reported ($5.29) EPS for the quarter, topping analysts’ consensus estimates of ($5.88) by $0.59. As a group, analysts expect that Aprea Therapeutics will post -3.09 EPS for the current year.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies.
Read More: Limitations to arbitrage trading
Get a free copy of the Zacks research report on Aprea Therapeutics (APRE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.